Zydus Cadila gets approval from USFDA for breast cancer drug
Zydus Cadila, the major drug firm, has received the final approval from the U.S. Food and Drug Administration(USFDA) to market Exemestane tablets. The drug will be used for the treatment of breast cancer. The drug is made in the strength of 25 mg. The company will manufacture the drug at its group’s formulations SEZ facility in Ahmedabad.